How Tech Innovations Impact Cardiac Care
Bio Spectrum|September 2021
Cardiac care has seen a transformation over the years with technology playing an important role. Armed with Artificial intelligence (AI) and machine learning (ML), cardiac care providers, with the right technology, have received the right impetus to revolutionise treatment mechanisms. Let us delve into the new technologies which the industry is offering to mankind and decipher the way forward.
Sanjiv Das

Cardiovascular diseases (CVD) have been on the rise across the globe and have seen exponential growth due to lifestyle disorders. To address this growing concern, the World Heart Federation observes September 29 as ‘World Heart Day’, every year. This year the primary goal for World Heart Day 2021 is ‘Globally harnessing the power of digital health to improve awareness, prevention and management of CVD’.

Cardiovascular diseases such as ischemic heart disease and stroke account for 17.7 million deaths in India and a significant patient pool involves younger population, according to the World Health Organisation (WHO). COVID-19 pandemic has added fuel to fire as it has been found that the virus can act as an independent driver for heart attack. Having said that, the world is witnessing a plethora of technological innovations in this space, saving numerous lives. India is not far behind and the country has witnessed significant improvements in heart care in the past decade.

According to a recent report by Mordor Intelligence, the market for cardiovascular devices in India consists of several global players along with the local players. However, the number of local players in the country is less and the market is dominated by global companies such as Abbott, Boston Scientific, Medtronic, etc. Since India is a growing economy, more global companies are expected to penetrate the market in the coming years.

New age technological advancements

Healthcare across the world has witnessed transition to new business models in order to improve patient care and operating efficiencies. Some of the recent advancements include Artificial intelligence (AI), advanced algorithms, and predictive analytics facilitating early detection and treatment of critically ill patients, in improving outcomes and providing value-based care. Then comes remote connected care that allows electrocardiogram (ECG) diagnosis using cloud technology and bluetooth-enabled cardiac devices which measure the parameters and transmit them back to healthcare providers without physically visiting the clinic.

American medical device firm Abbott has recently launched its Amplatzer Piccolo Occluder in India, the world’s first medical device that can be implanted in tiniest babies (weighing as little as 700 gms) using a minimally invasive procedure to treat patent ductus arteriosus, or PDA. The Amplatzer Piccolo, a device even smaller than a pea, now offers hope to premature infants and newborns who need corrective treatment, and who may be non-responsive to medicine and are at high risk to undergo corrective surgery.

Last year, Abbott also launched clip delivery system, a minimally invasive heart valve repair device to treat mitral regurgitation in India. The clip device repairs leaky mitral valves without open-heart surgery and is delivered to the heart through a vein in the leg.

Continue reading your story on the app

Continue reading your story in the magazine

MORE STORIES FROM BIO SPECTRUMView All

How Tech Innovations Impact Cardiac Care

Cardiac care has seen a transformation over the years with technology playing an important role. Armed with Artificial intelligence (AI) and machine learning (ML), cardiac care providers, with the right technology, have received the right impetus to revolutionise treatment mechanisms. Let us delve into the new technologies which the industry is offering to mankind and decipher the way forward.

6 mins read
Bio Spectrum
September 2021

Mynvax Offers ‘Warm Vaccine' For COVID-19

Biotech startup Mynvax, incubated at the Indian Institute of Science (IISc) in Bengaluru, has developed heat-tolerant COVID-19 vaccine formulations.

1 min read
Bio Spectrum
September 2021

“R&D outsourcing has become a ‘must have' than ‘good-to have' strategy”

Aragen Life Sciences (formerly GVK BIO), a leading contract research and development organisation headquartered in Hyderabad, is marking its transition to a new brand identity in its 20th year. Established in 2001, the company is poised for growth in the outsourced discovery, development, and manufacturing services sector across both large and small molecule platforms with new investments and collaborations. In conversation with BioSpectrum, Manni Kantipudi, Chief Executive Officer, Aragen Life Sciences, Hyderabad reveals more about the company’s recent rebranding and growth plans. Edited excerpts;

4 mins read
Bio Spectrum
September 2021

Premas Biotech to commercialise VLP vaccine tech against Delta variant

Gurugram-based Premas Biotech has signed a licensing deal with Oravax Medical for the development and commercialisation of its virus-like-particle COVID-19 vaccine technology.

1 min read
Bio Spectrum
September 2021

SARS-CoV-2: A Biochemical Treatise on its Past, Present & Future

The SARS-CoV-2 pandemic is unprecedented but equally unprecedented is the contribution of scientists who have helped us in understanding the mechanisms by which it infects human beings and also, developing a variety of vaccines to protect the masses, in a year’s time, which can be called truly groundbreaking. This article gives an overview of the progress made by scientists around the world working round the clock in developing an understanding of the SARS-CoV-2 evolution and COVID-19 disease pathogenesis, and also makes an attempt to suggest the possible ways of coping with this pandemic if we have to co-exist with it forever!

4 mins read
Bio Spectrum
September 2021

Merck launches Pergoveris Pen for fertility treatment in India

Merck Specialties, the healthcare business of Merck in India, has launched Pergoveris Pen for advanced infertility treatment in India.

1 min read
Bio Spectrum
September 2021

GUNG-HO PHARMA R&D INVESTMENTS SURPASS $3B

While the pharmaceutical industry helped combat COVID-19, from R&D actions on potential treatment strategies to balancing the medicines supply chain in the time of crisis, it struggled to maintain the natural market flow. As a result, many pharma companies had to abort some of their ongoing R&D investment plans. However for FY20-21, the average R&D expenses constituted 7.2 per cent of the total revenues of the pharma companies, with Lupin, Alembic Pharma and Dr. Reddy’s spending more than others. The cumulative R&D expenditure of the leading 10 pharma companies has been around Rs 10,627 crore ($1.43 billion) in the previous fiscal. This figure eventually reaches an approximate amount of Rs 22,500 crore ($3.03 billion) after considering the cumulative expenditure by other small and medium players of the India pharma industry.

10+ mins read
Bio Spectrum
September 2021

Glenmark ties up with SaNOtize to commercialise COVID-19 nasal spray

Mumbai-based Glenmark Pharmaceuticals and Canadian biotech firm SaNOtize Research & Development Corporation

1 min read
Bio Spectrum
September 2021

CEPI prioritises Rift Valley fever vax

Sep 01, Norway-based Coalition for Epidemic Preparedness Innovations (CEPI) has signed an implementing partner agreement with Integrum Scientific (US) as part of its ongoing efforts to combat Rift Valley fever (RVF)—one of its priority diseases with epidemic potential.

1 min read
Bio Spectrum
September 2021

3D printing moulds healthcare innovations

Pharmaceuticals, bio-medicine, aviation, and automobiles industries have rapidly adopted 3D printing over the years, worldwide, to develop new solutions and prototypes. It is also helping many industries, healthcare, in particular, increase productivity. Despite all its advantages, 3D printing technology is currently posing a number of challenges in the market such as initial costs, limitation to the metals and plastics used for 3D printing, lack of policy standardisation, etc.

7 mins read
Bio Spectrum
September 2021